The University of Pennsylvania is suing three leading insulin makers and companies that negotiate drug price deals for insurance plans, accusing them of a scheme to drive up prices of a medication ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should see earnings gains through the end of the decade.

CVS Caremark estimates between 25 to 30 million people use ... Though the two drugs are both approved for weight loss, a study published in May funded by Eli Lilly found that patients on Zepbound were ...

Eli Lilly on Thursday downplayed CVS Health’s decision to drop the company’s obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker still ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay programs at $499 monthly ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Eli Lilly's CEO waved off the Novo Nordisk-CVS GLP-1 formulary deal as he focuses on the future of the company's obesity pipeline.

CVS Health Corp. will administer Eli Lilly and Co.’s COVID-19 treatment in patients’ homes and in long-term care facilities through a program with the U.S. government’s Operation Warp Speed ...

CVS Health Corp. will administer Eli Lilly and Co.’s COVID-19 treatment in patients’ homes and in long-term care facilities through a program with the U.S. government’s Operation Warp Speed ...

Goldman Sachs cuts Eli Lilly's price target to $883, citing PBM-related uncertainty after CVS dropped Zepbound. BofA keeps $1,000 price target, saying Zepbound remains superior and CVS move is not ...

CVS Health Corp said on Wednesday it would administer Eli Lilly & Co's experimental antibody treatment to COVID-19 patients in their homes and in long-term care facilities through a U.S ...